Synaptogenix Inc (SNPX)

[Cyosol]

Again, your price target assumes that results will be positive, even though they have failed to meet primary endpoints twice.

Subgroup analysis looks promising, but that's no guarantee for success.

13G includes the same old institutions loading up on more below market price shares and warrants that they can offload for an immediate profit once the SEC registers them.

Patent portfolio is solid, but that too does not guarantee a positive trial outcome. Neither does launching a new trial.

Is there a lot of potential here? Definitely, but I doubt we'll see any big moves here until results are out. Maybe the occasional pump & dump but I'm sure the real action won't happen until next year.